vs

Side-by-side financial comparison of Crocs, Inc. (CROX) and ResMed (RMD). Click either name above to swap in a different company.

ResMed is the larger business by last-quarter revenue ($1.4B vs $921.5M, roughly 1.5× Crocs, Inc.). ResMed runs the higher net margin — 27.6% vs 14.9%, a 12.7% gap on every dollar of revenue. On growth, ResMed posted the faster year-over-year revenue change (11.0% vs -1.7%). Over the past eight quarters, ResMed's revenue compounded faster (7.8% CAGR vs -8.9%).

Crocs, Inc. is an American footwear company based in Broomfield, Colorado. It manufactures and markets the Crocs brand of foam footwear. Crocs, Inc. terms these "clogs," but they do not contain wood like traditional clogs.

ResMed Inc. is a medical equipment company based in San Diego, California, and founded in Australia. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. Resmed produced hundreds of thousands of ventilators and bilevel devices to help treat the respiratory symptoms of patients with COVID-19.

CROX vs RMD — Head-to-Head

Bigger by revenue
RMD
RMD
1.5× larger
RMD
$1.4B
$921.5M
CROX
Growing faster (revenue YoY)
RMD
RMD
+12.7% gap
RMD
11.0%
-1.7%
CROX
Higher net margin
RMD
RMD
12.7% more per $
RMD
27.6%
14.9%
CROX
Faster 2-yr revenue CAGR
RMD
RMD
Annualised
RMD
7.8%
-8.9%
CROX

Income Statement — Q1 FY2026 vs Q4 FY2026

Metric
CROX
CROX
RMD
RMD
Revenue
$921.5M
$1.4B
Net Profit
$137.6M
$392.6M
Gross Margin
56.8%
61.8%
Operating Margin
21.8%
34.6%
Net Margin
14.9%
27.6%
Revenue YoY
-1.7%
11.0%
Net Profit YoY
-14.1%
13.9%
EPS (diluted)
$2.71
$2.68

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CROX
CROX
RMD
RMD
Q2 26
$1.4B
Q1 26
$921.5M
$1.4B
Q4 25
$957.6M
$1.4B
Q3 25
$996.3M
$1.3B
Q2 25
$1.1B
$1.3B
Q1 25
$937.3M
$1.3B
Q4 24
$989.8M
$1.3B
Q3 24
$1.1B
$1.2B
Net Profit
CROX
CROX
RMD
RMD
Q2 26
$392.6M
Q1 26
$137.6M
$398.7M
Q4 25
$105.2M
$392.6M
Q3 25
$145.8M
$348.5M
Q2 25
$-492.3M
$379.7M
Q1 25
$160.1M
$365.0M
Q4 24
$368.9M
$344.6M
Q3 24
$199.8M
$311.4M
Gross Margin
CROX
CROX
RMD
RMD
Q2 26
61.8%
Q1 26
56.8%
62.2%
Q4 25
54.7%
61.8%
Q3 25
58.5%
61.5%
Q2 25
61.7%
60.8%
Q1 25
57.8%
59.3%
Q4 24
57.9%
58.6%
Q3 24
59.6%
58.6%
Operating Margin
CROX
CROX
RMD
RMD
Q2 26
34.6%
Q1 26
21.8%
34.9%
Q4 25
15.3%
34.6%
Q3 25
20.8%
33.4%
Q2 25
-37.2%
33.7%
Q1 25
23.8%
33.0%
Q4 24
20.2%
32.5%
Q3 24
25.4%
31.6%
Net Margin
CROX
CROX
RMD
RMD
Q2 26
27.6%
Q1 26
14.9%
27.9%
Q4 25
11.0%
27.6%
Q3 25
14.6%
26.1%
Q2 25
-42.8%
28.2%
Q1 25
17.1%
28.3%
Q4 24
37.3%
26.9%
Q3 24
18.8%
25.4%
EPS (diluted)
CROX
CROX
RMD
RMD
Q2 26
$2.68
Q1 26
$2.71
$2.74
Q4 25
$1.79
$2.68
Q3 25
$2.70
$2.37
Q2 25
$-8.82
$2.58
Q1 25
$2.83
$2.48
Q4 24
$6.25
$2.34
Q3 24
$3.36
$2.11

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CROX
CROX
RMD
RMD
Cash + ST InvestmentsLiquidity on hand
$130.9M
$1.4B
Total DebtLower is stronger
$1.3B
$663.8M
Stockholders' EquityBook value
$1.4B
$6.3B
Total Assets
$4.3B
$8.5B
Debt / EquityLower = less leverage
0.93×
0.11×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CROX
CROX
RMD
RMD
Q2 26
$1.4B
Q1 26
$130.9M
$1.7B
Q4 25
$130.4M
$1.4B
Q3 25
$154.0M
$1.4B
Q2 25
$200.6M
$1.2B
Q1 25
$166.5M
$932.7M
Q4 24
$180.5M
$521.9M
Q3 24
$186.1M
$426.4M
Total Debt
CROX
CROX
RMD
RMD
Q2 26
$663.8M
Q1 26
$1.3B
$664.1M
Q4 25
$403.9M
Q3 25
$408.7M
Q2 25
$658.4M
Q1 25
$663.1M
Q4 24
$662.9M
Q3 24
$667.6M
Stockholders' Equity
CROX
CROX
RMD
RMD
Q2 26
$6.3B
Q1 26
$1.4B
$6.5B
Q4 25
$1.3B
$6.3B
Q3 25
$1.4B
$6.1B
Q2 25
$1.4B
$6.0B
Q1 25
$2.0B
$5.5B
Q4 24
$1.8B
$5.3B
Q3 24
$1.7B
$5.2B
Total Assets
CROX
CROX
RMD
RMD
Q2 26
$8.5B
Q1 26
$4.3B
$8.8B
Q4 25
$4.2B
$8.5B
Q3 25
$4.3B
$8.3B
Q2 25
$4.5B
$8.2B
Q1 25
$5.1B
$7.6B
Q4 24
$4.8B
$7.1B
Q3 24
$4.7B
$7.2B
Debt / Equity
CROX
CROX
RMD
RMD
Q2 26
0.11×
Q1 26
0.93×
0.10×
Q4 25
0.06×
Q3 25
0.07×
Q2 25
0.11×
Q1 25
0.12×
Q4 24
0.13×
Q3 24
0.13×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CROX
CROX
RMD
RMD
Operating Cash FlowLast quarter
Free Cash FlowOCF − Capex
$-98.9M
FCF MarginFCF / Revenue
-10.7%
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$642.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CROX
CROX
RMD
RMD
Q2 26
Q1 26
Q4 25
$252.5M
$339.7M
Q3 25
$239.3M
$457.3M
Q2 25
$285.8M
$538.8M
Q1 25
$-67.2M
$578.7M
Q4 24
$321.9M
$308.6M
Q3 24
$296.9M
$325.5M
Free Cash Flow
CROX
CROX
RMD
RMD
Q2 26
Q1 26
$-98.9M
Q4 25
$246.4M
$311.2M
Q3 25
$226.2M
$414.4M
Q2 25
$269.2M
$508.2M
Q1 25
$-82.6M
$557.9M
Q4 24
$303.4M
$288.0M
Q3 24
$278.8M
$307.7M
FCF Margin
CROX
CROX
RMD
RMD
Q2 26
Q1 26
-10.7%
Q4 25
25.7%
21.9%
Q3 25
22.7%
31.0%
Q2 25
23.4%
37.7%
Q1 25
-8.8%
43.2%
Q4 24
30.7%
22.5%
Q3 24
26.3%
25.1%
Capex Intensity
CROX
CROX
RMD
RMD
Q2 26
Q1 26
Q4 25
0.6%
2.0%
Q3 25
1.3%
3.2%
Q2 25
1.4%
2.3%
Q1 25
1.6%
1.6%
Q4 24
1.9%
1.6%
Q3 24
1.7%
1.5%
Cash Conversion
CROX
CROX
RMD
RMD
Q2 26
Q1 26
Q4 25
2.40×
0.87×
Q3 25
1.64×
1.31×
Q2 25
1.42×
Q1 25
-0.42×
1.59×
Q4 24
0.87×
0.90×
Q3 24
1.49×
1.05×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons